Details for Patent: 6,566,343
✉ Email this page to a colleague
Title: | High affinity nucleic acid ligands of complement system proteins |
Abstract: | Methods are described for the identification and preparation of high-affinity Nucleic Acid Ligands to Complement System Proteins. Methods are described for the identification and preparation of high affinity Nucleic Acid Ligands to Complement System Proteins C1q, C3 and C5. Included in the invention are specific RNA ligands to C1q, C3 and C5 identified by the SELEX method. |
Inventor(s): | Biesecker; Gregory (Boulder, CO), Gold; Larry (Boulder, CO) |
Assignee: | Gilead Sciences, Inc. (Foster City, CA) |
Filing Date: | Jan 03, 2002 |
Application Number: | 10/037,282 |
Claims: | 1. A method for treating a Complement System-mediated disease comprising administering to a patient in need thereof a pharmaceutically effective amount of a Nucleic Acid Ligand of a Complement System Protein, wherein said Nucleic Acid Ligand is selected from the group consisting of SEQ ID NOS:5-155. 2. A method of treating an infection caused by bacterial or viral cells comprising: a) conjugating a Nucleic Acid Ligand that has been generated to a bacterial cell surface target of said bacteria or viral particle target of said virus with a C1q Nucleic Acid Ligand; and b) administering the conjugate to a patient in need thereof in an amount effective to activate the Complement System and lyse the bacterial or viral cells. 3. A method of killing tumor cells in a patient comprising: a) conjugating a Nucleic Acid Ligand that has been generated to a tumor cell surface target with a C1q Nucleic Acid Ligand; and b) administering the conjugate to the patient in need thereof in an amount effective to activate the Complement System and kill the tumor or tumor cell. |